Health Catalyst Gestione
Gestione criteri di controllo 3/4
Health Catalyst Il CEO è Dan Burton, nominato in Oct2012, ha un mandato di 12.08 anni. possiede direttamente 1.42% delle azioni della società, per un valore di $ 6.51M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.2 anni e 7.5 anni.
Informazioni chiave
Dan Burton
Amministratore delegato
n/a
Compenso totale
| Percentuale dello stipendio del CEO | n/a |
| Mandato del CEO | 12.1yrs |
| Proprietà del CEO | 1.4% |
| Durata media del management | 2.2yrs |
| Durata media del Consiglio di amministrazione | 7.5yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Health Catalyst: Still Optimistic On Achieving Adjusted EBITDA Targets
Sep 24Health Catalyst, Inc.'s (NASDAQ:HCAT) Shares Lagging The Industry But So Is The Business
Jul 17
Health Catalyst: Stellar Earnings Growth Projected
Jun 26Health Catalyst, Inc. (NASDAQ:HCAT) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 12Benign Growth For Health Catalyst, Inc. (NASDAQ:HCAT) Underpins Its Share Price
Apr 04Health Catalyst: Achieving FY28 Long-Term Guidance Is Possible
Mar 09Health Catalyst Looks To Slim Down As It Faces Industry Headwinds (Downgrade)
Feb 16Is Health Catalyst (NASDAQ:HCAT) A Risky Investment?
Jan 27What Health Catalyst, Inc.'s (NASDAQ:HCAT) 25% Share Price Gain Is Not Telling You
Dec 24Is Health Catalyst, Inc. (NASDAQ:HCAT) Trading At A 47% Discount?
Dec 15Is Health Catalyst (NASDAQ:HCAT) Weighed On By Its Debt Load?
Oct 24Subdued Growth No Barrier To Health Catalyst, Inc.'s (NASDAQ:HCAT) Price
Jul 31Is Health Catalyst (NASDAQ:HCAT) Using Too Much Debt?
Jun 27Is Health Catalyst (NASDAQ:HCAT) Using Too Much Debt?
Feb 22Health Catalyst, Inc. (NASDAQ:HCAT) Shares Could Be 22% Above Their Intrinsic Value Estimate
Dec 06Is Health Catalyst (NASDAQ:HCAT) Using Debt In A Risky Way?
Nov 03Health Catalyst: Looking For A Turnaround For This 'Bio Boom' Candidate
Oct 14Health Catalyst names Kevin Freeman as Chief Growth Officer, Tarah Bryan as Chief Marketing Officer, Dave Ross as Chief Technology Officer
Sep 07Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$79m |
| Jun 30 2024 | n/a | n/a | -US$86m |
| Mar 31 2024 | n/a | n/a | -US$106m |
| Dec 31 2023 | n/a | n/a | -US$118m |
| Sep 30 2023 | n/a | n/a | -US$124m |
| Jun 30 2023 | n/a | n/a | -US$147m |
| Mar 31 2023 | n/a | n/a | -US$148m |
| Dec 31 2022 | US$4m | US$150k | -US$137m |
| Sep 30 2022 | n/a | n/a | -US$151m |
| Jun 30 2022 | n/a | n/a | -US$145m |
| Mar 31 2022 | n/a | n/a | -US$147m |
| Dec 31 2021 | US$6m | US$300k | -US$153m |
| Sep 30 2021 | n/a | n/a | -US$147m |
| Jun 30 2021 | n/a | n/a | -US$135m |
| Mar 31 2021 | n/a | n/a | -US$126m |
| Dec 31 2020 | US$5m | US$315k | -US$115m |
| Sep 30 2020 | n/a | n/a | -US$86m |
| Jun 30 2020 | n/a | n/a | -US$99m |
| Mar 31 2020 | n/a | n/a | -US$181m |
| Dec 31 2019 | US$4m | US$350k | -US$241m |
| Sep 30 2019 | n/a | n/a | -US$304m |
| Jun 30 2019 | n/a | n/a | -US$282m |
| Mar 31 2019 | n/a | n/a | -US$190m |
| Dec 31 2018 | US$5m | US$315k | -US$114m |
Compensazione vs Mercato: Dati insufficienti per stabilire se la retribuzione totale di Dan sia ragionevole rispetto ad aziende di dimensioni simili nel mercato US.
Compensazione vs guadagni: La retribuzione di Dan è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Dan Burton (49 yo)
12.1yrs
Mandato
Mr. Daniel D. Burton, also known as Dan, has been the Chief Executive Officer of Health Catalyst, Inc. since October 2012 and has been its Director since September 2011. Mr. Burton has strategy and leaders...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 12.1yrs | Nessun dato | 1.42% $ 6.5m | |
| Chief Financial Officer | less than a year | US$823.62k | 0.19% $ 860.4k | |
| General Counsel & Secretary of the Board | 1.5yrs | US$946.31k | 0.17% $ 761.0k | |
| Chief People Officer | 6.8yrs | US$1.06m | 0.029% $ 131.2k | |
| Chief Operating Officer | less than a year | Nessun dato | 0.051% $ 235.6k | |
| Chief Technology Officer | 2.2yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Investor Relations and Financial Planning & Analysis | 3.8yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Marketing & Communications | less than a year | Nessun dato | Nessun dato | |
| Chief Strategy Officer & Senior VP of Corporate Development | no data | Nessun dato | Nessun dato | |
| Senior Vice President of International | 5.5yrs | Nessun dato | Nessun dato | |
| Senior VP & Chief Clinical Officer | no data | Nessun dato | Nessun dato | |
| Chief Client Success Officer | no data | Nessun dato | Nessun dato |
2.2yrs
Durata media
46yo
Età media
Gestione esperta: Il team dirigenziale di HCAT è considerato esperto (durata media dell'incarico 2.2 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 13.2yrs | Nessun dato | 1.42% $ 6.5m | |
| Independent Chairman | 8.8yrs | US$316.16k | 0.18% $ 830.8k | |
| Independent Director | 4.8yrs | US$233.49k | 0.076% $ 349.7k | |
| Independent Director | 4.8yrs | US$237.25k | 0.073% $ 336.7k | |
| Independent Director | 8.6yrs | US$244.77k | 0.058% $ 267.7k | |
| Independent Director | 7.5yrs | US$244.77k | 0.092% $ 423.2k | |
| Independent Director | 1.3yrs | Nessun dato | Nessun dato |
7.5yrs
Durata media
60yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di HCAT sono considerati esperti (durata media dell'incarico 7.5 anni).